High Blood Pressure

Clinical Trial Finder

Many patients with high blood pressure are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)

Condition:   Pulmonary Arterial Hypertension
Intervention:   Drug: Remodulin® (Intravenous Treprostinil)
Sponsor:   United Therapeutics
Completed - verified February 2017

Inferior Vena Cava Sonography in Hemodialysis Patients and Quality of Life

Conditions:   Hemodialysis Complication;   End Stage Renal Disease
Intervention:   Diagnostic Test: sonographic measurement of inferior vena cava diameter
Sponsor:   Hadassah Medical Organization
Not yet recruiting - verified February 2017

Effect of Dry-weight Probing Guided by Lung-Ultrasound on Ambulatory Aortic Blood Pressure and Arterial Stiffness in Hemodialysis Patients (LUST Sub-Study)

Conditions:   Chronic Kidney Disease;   Hemodialysis;   Hypertension
Interventions:   Procedure: Extra-vascular lung water measurements by ultrasound;   Other: Standard protocol of fluid management in hemodialysis
Sponsors:   Carmine Zoccali;   Aristotle University of Thessaloniki, Thessaloniki, Greece;   CNR-IBIM Clinical Epidemiology of Renal Diseases and Hypertension Unit, Reggio, Italy;   University Clinical Centre of Maribor, Slovenia
Recruiting - verified February 2017

Respiratory Monitoring During Right Heart

Conditions:   Pulmonary Hypertension;   Heart Failure
Intervention:  
Sponsors:   Rambam Health Care Campus;   Technion, Israel Institute of Technology
Not yet recruiting - verified February 2017

The Effects of Commercial Air Travel on Patients Suffering From Pulmonary Hypertension

Conditions:   Pulmonary Hypertension;   Pulmonary Arterial Hypertension
Intervention:  
Sponsors:   University of Giessen;   Universitätsklinikum Hamburg-Eppendorf;   DRK Kliniken Berlin Köpenick, Berlin, Germany;   University Hospital, Zürich;   University Hospital Carl Gustav Carus
Recruiting - verified February 2017

Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF)

Condition:   Pulmonary Hypertension Associated With HFpEF
Intervention:   Drug: Oral Treprostinil
Sponsor:   United Therapeutics
Not yet recruiting - verified February 2017

Randomized Double-blind Placebo-controlled Trial Assessing the Efficacy of Standard and Low Dose Hydrochlorothiazide Treatment in the Prevention of Recurrent Nephrolithiasis

Condition:   Nephrolithiasis
Interventions:   Drug: Placebo oral capsule;   Drug: 12.5 mg hydrochlorothiazide;   Drug: 25.0 mg hydrochlorothiazide;   Drug: 50.0 mg hydrochlorothiazide
Sponsor:   University Hospital Inselspital, Berne
Not yet recruiting - verified February 2017

Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF)

Conditions:   Pulmonary Hypertension;   Heart Failure With a Preserved Ejection Fraction
Interventions:   Drug: Oral treprostinil;   Drug: Placebo
Sponsor:   United Therapeutics
Not yet recruiting - verified February 2017

Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD)

Condition:   Pulmonary Hypertension Associated With Sickle Cell Disease
Interventions:   Drug: Oral Treprostinil;   Drug: Placebo
Sponsor:   United Therapeutics
Not yet recruiting - verified February 2017

Evaluation of the Efficacy Safety and Tolerability of Nitric Oxide Given Intermittently Via Inhalation to Subjects With Bronchiolitis

Condition:   Bronchiolitis
Interventions:   Drug: Nitric Oxide;   Other: Supportive treatment
Sponsor:   Advanced Inhalation Therapies Ltd
Not yet recruiting - verified February 2017

Assessment of Home Tonometry in Glaucoma

Conditions:   Glaucoma;   Intraocular Pressure
Intervention:   Device: iCare home tonometer
Sponsor:   NHS Lothian
Recruiting - verified February 2017

Effect of Total Intravenous Anaesthesia With Propofol on Postoperative Pain After Bilateral Third Molar Surgery

Condition:   Postoperative Pain
Interventions:   Drug: propofol;   Drug: Sevoflurane
Sponsor:   The University of Hong Kong
Active, not recruiting - verified February 2017

Effect of Exercise on Selected Anthropometric,Biochemical and Physiological Variables Among Hypertensive Patients

Condition:   Hypertension
Interventions:   Other: Aerobic exercise .;   Other: Resistance exercise;   Other: Aerobic and resistance exercise
Sponsor:   Mekelle University
Recruiting - verified February 2017

A Novel Approach for Transjugular Intrahepatic Portocaval Shunt Creation Using Real-time Three Dimensional Roadmap

Condition:   Portal Hypertension
Intervention:   Other: 3d roadmap guidance
Sponsor:   West China Hospital
Recruiting - verified February 2017

OEIS Outcome Data Registry

Condition:   Peripheral Arterial Disease
Intervention:  
Sponsors:   Outpatient Endovascular and Interventional Society;   Syntactx
Recruiting - verified February 2017

Efficacy and Safety of S-amlodipine 2,5 mg and 5 mg in Hypertension Patients

Condition:   Hypertension
Intervention:   Drug: S-NOR (s-amlodipine) 2,5 mg & 5 mg tablet
Sponsor:   Neutec Ar-Ge San ve Tic A.Ş
Completed - verified February 2017

To Evaluate Real-world Safety, Effectiveness and Appropriate Use of Micatrio® Combination Tablets Treatment in Patients With Hypertension

Condition:   Hypertension
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2017

Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH

Condition:   Pulmonary Arterial Hypertension
Interventions:   Drug: Parenteral Remodulin (treprostinil) injection;   Drug: Oral Treprostinil
Sponsor:   United Therapeutics
Not yet recruiting - verified February 2017

To Compare the Efficacy of Combination Therapy vs Monotherapy for Pulmonary Arterial Hypertension in Systemic Sclerosis

Condition:   Associated Pulmonary Arterial Hypertension
Interventions:   Drug: Sildenafil 20mg and Bosentan 62.5mg;   Drug: Sildenafil 20mg and Placebo
Sponsor:   Postgraduate Institute of Medical Education and Research
Recruiting - verified February 2017

The Effect of High Dose Methylprednisolone on Nailfold in Early Systemic Sclerosis ( SSc )

Conditions:   Systemic Sclerosis;   Raynaud Phenomena
Interventions:   Drug: Methylprednisolone;   Other: sodium chloride
Sponsor:   Radboud University
Enrolling by invitation - verified January 2017

Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension

Condition:   Pulmonary Arterial Hypertension
Interventions:   Drug: Oral Treprostinil;   Drug: Placebo
Sponsor:   United Therapeutics
Not yet recruiting - verified December 2016

Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD

Conditions:   Pulmonary Hypertension;   Chronic Obstructive Pulmonary Disease
Intervention:   Drug: Inhaled Treprostinil
Sponsor:   United Therapeutics
Not yet recruiting - verified February 2017

Evaluation of Celecoxib Effects on Amlodipine in Subjects With Existing Hypertension Requiring Antihypertensives

Condition:   Hypertension
Interventions:   Drug: Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule;   Drug: Over-encapsulated 10 mg amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule;   Drug: Matched placebo tablet for over-encapsulated amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule
Sponsor:   Kitov Pharmaceuticals, Ltd.
Recruiting - verified February 2017

RCT to Determine the Efficacy of Combining Hemospray With Medical Treatment in Acute Variceal Bleeding

Condition:   Variceal Hemorrhage
Interventions:   Device: Hemospray;   Drug: Octreotide;   Biological: Blood transfusion;   Drug: Ceftriaxone
Sponsors:   Theodor Bilharz Research Institute;   Université Libre de Bruxelles
Recruiting - verified February 2017

Effects of Short-term Interventions for a Healthy Lifestyle on the Human Lipidome in Subjects With Metabolic Syndrome

Conditions:   Metabolic Syndrome;   NAFLD;   Obesity;   Hypertension
Interventions:   Behavioral: Lifestyle intervention (physical activity);   Dietary Supplement: Lifestyle intervention (PUFA/isomaltulose-enriched muffin)
Sponsor:   German Institute of Human Nutrition
Recruiting - verified February 2017

Subcutaneous Median Nerve Neuromodulation For Drug-Treatment Resistant Hypertension.

Condition:   Resistant Hypertension
Intervention:   Device: eCoin System
Sponsor:   Valencia Technologies Corporation
Withdrawn - verified February 2017

Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome

Condition:   Metabolic Syndrome
Intervention:   Drug: 3-V Bioscience-2640
Sponsors:   University of Missouri-Columbia;   3V Biosciences, Inc.
Recruiting - verified October 2016

Validation of Promising Biomarker Assays to Assess Their Diagnostic Performance Characteristics

Condition:   Acute Febrile Illnesses
Intervention:   Device: CRP
Sponsors:   Foundation for Innovative New Diagnostics, Switzerland;   HAWASSA UNIVERSITY COLLEGE OF MEDICINE AND HEALTH SCIENCES;   MALAWI EPIDEMIOLOGY AND INTERVENTION RESEARCH UNIT;   Instituto Nacional de Infectologia Evandro Chagas
Not yet recruiting - verified February 2017

Comprehensive Treatment of Angina in Women With Microvascular Dysfunction

Conditions:   Angina Pectoris;   Coronary Microvascular Disease
Interventions:   Dietary Supplement: Diet;   Behavioral: Training;   Drug: Medication (with statin and ACE-inhibition)
Sponsors:   Bispebjerg Hospital;   University Hospital Bispebjerg and Frederiksberg;   Cambridge Weight Plan Limited
Recruiting - verified February 2017

Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy

Condition:   Pulmonary Arterial Hypertension
Interventions:   Drug: Adempas (Riociguat, BAY63-2521);   Drug: Sildenafil;   Drug: Tadalafil
Sponsor:   Bayer
Recruiting - verified February 2017

Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial

Conditions:   Congestive Heart Failure;   Heart Failure, Left-Sided;   Left-Sided Heart Failure
Interventions:   Drug: Albuterol;   Other: Saline placebo
Sponsor:   Mayo Clinic
Recruiting - verified February 2017

BAROSTIM THERAPY™ In Resistant Hypertension

Condition:   Hypertension
Intervention:   Device: Barostim Neo™ System
Sponsor:   CVRx, Inc.
Recruiting - verified February 2017

Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension

Condition:   Essential Hypertension
Interventions:   Drug: CS-3150;   Drug: olmesartan medoxomil
Sponsor:   Daiichi Sankyo Co., Ltd.
Active, not recruiting - verified February 2017

Preliminary Testing of the Vitaliti CVSM Wearable, Vitaliti Spirotoscope, and Vitaliti IVD Station

Conditions:   Urinary Tract Infection;   Diabetes Mellitus;   Atrial Fibrillation;   OSA;   COPD;   Pneumonia;   Acute Otitis Media;   Leukocytosis;   Iron Deficient Anemia;   Hypertension;   Healthy Volunteers
Intervention:   Device: Vitaliti
Sponsor:   Cloud DX Inc.
Enrolling by invitation - verified February 2017

Acupuncture Lowering Blood Pressure for Secondary Prevention of Stroke

Condition:   Cerebral Infarction
Intervention:   Device: acupuncture
Sponsors:   First Teaching Hospital of Tianjin University of Traditional Chinese Medicine;   State Administration of Traditional Chinese Medicine of the People's Republic of China
Recruiting - verified February 2017

iPhone App Compared to Standard Riva-Rocci (RR)-Measurement During Stress Testing

Condition:   Blood Pressure
Interventions:   Device: cuff device;   Device: iphone
Sponsor:   University Hospital, Basel, Switzerland
Completed - verified February 2017

Study of CS-3150 in Patients With Severe Hypertension

Condition:   Severe Hypertension
Intervention:   Drug: CS-3150
Sponsor:   Daiichi Sankyo Co., Ltd.
Active, not recruiting - verified February 2017

Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)

Condition:   Hypertension, Pulmonary
Intervention:   Drug: Ventavis (Iloprost, BAYQ6256)
Sponsor:   Bayer
Recruiting - verified February 2017

Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria

Condition:   Hypertension
Intervention:   Drug: CS-3150
Sponsor:   Daiichi Sankyo Co., Ltd.
Active, not recruiting - verified February 2017

Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients

Conditions:   Portal Hypertension;   Liver Cirrhosis
Interventions:   Drug: Ifetroban;   Drug: Placebo
Sponsor:   Cumberland Pharmaceuticals
Not yet recruiting - verified February 2017

HYPID (Pulmonary Hypertension in Interstitial Lung Disease) EXTENSION

Conditions:   Pulmonary Arterial Hypertension;   Diffuse Interstitial Lung Disease
Intervention:  
Sponsors:   Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires;   Hospices Civils de Lyon
Recruiting - verified February 2017

The Sleepless Brain: Neuroimaging Support for a Differential Diagnosis of Insomnia

Condition:   Insomnia
Intervention:   Other: MRI
Sponsors:   University Hospital, Bordeaux;   Institut des Maladies Neurodégénératives (UMR5293)
Recruiting - verified February 2017

Observational Study to Evaluate the Safety of DILATREND SR Cap. in Korean Patients With Essential Hypertension, Chronic Stable Angina and Congestive Heart Failure

Conditions:   Essential Hypertension;   Chronic Stable Angina;   Congestive Heart Failure
Intervention:  
Sponsor:   Chong Kun Dang Pharmaceutical
Enrolling by invitation - verified February 2017

Evaluation of the Efficacy of Citrulline Supplementation on the Delay of Delivery for Women Hospitalized for Pre-eclampsia (CITRUPE)

Conditions:   Pre-eclampsia;   Pregnancy
Interventions:   Drug: Citrulline;   Drug: Placebo
Sponsor:   Nantes University Hospital
Recruiting - verified February 2017

Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer

Condition:   Colorectal Neoplasms
Interventions:   Drug: BI 695502;   Drug: chemotherapy
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2017

Pilot Study of the Safety and Efficacy of Anakinra in Pulmonary Arterial Hypertension

Condition:   Pulmonary Arterial Hypertension
Intervention:   Drug: Anakinra
Sponsor:   Virginia Commonwealth University
Recruiting - verified February 2017

Evaluation of Gastroesophageal Varices by Transnasal Endoscopy.

Conditions:   Esophageal Varices;   Gastric Varices;   Hypertension Portal;   Liver Cirrhosis
Intervention:  
Sponsor:   Federal University of Minas Gerais
Enrolling by invitation - verified February 2017

A Physical Activity Program in End-state Liver Disease

Conditions:   End-stage Liver Disease (ESLD);   Liver Transplant;   Sarcopenia;   Poor Physical Fitness;   Cirrhosis;   Portal Hypertension
Interventions:   Other: Nutritional consultation;   Behavioral: Physical training program;   Behavioral: Behavioral modification therapy
Sponsor:   University of Arkansas
Enrolling by invitation - verified February 2017

Assessment of the Prevalence of Small Fiber Peripheral Neuropathy Among Non-diabetic Obese Patients

Condition:   Neuropathology
Intervention:   Device: Exams
Sponsor:   Groupe Hospitalier Paris Saint Joseph
Recruiting - verified May 2016

A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Subjects With Open-angle Glaucoma or Ocular Hypertension

Conditions:   Open-Angle Glaucoma;   Ocular Hypertension
Interventions:   Drug: Fixed Combination;   Drug: Bimatoprost;   Drug: Timolol
Sponsor:   ForSight Vision5, Inc.
Completed - verified February 2017

Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®

Conditions:   Open-angle Glaucoma;   Ocular Hypertension
Interventions:   Drug: Brinzolamide 1%/Brimonidine 0.2% suspension;   Drug: Brinzolamide/Brimonidine vehicle;   Drug: Travoprost 0.004%/Timolol 0.5% solution
Sponsor:   Alcon Research
Recruiting - verified February 2017

Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension

Condition:   Essential Hypertension
Intervention:   Drug: CS-3150
Sponsor:   Daiichi Sankyo Co., Ltd.
Active, not recruiting - verified February 2017

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

Conditions:   Scleroderma, Diffuse;   Scleroderma, Systemic;   Scleroderma, Limited;   Sclerosis, Progressive Systemic;   Skin Diseases;   Connective Tissue Diseases;   Pathologic Processes;   Autoimmune Diseases
Interventions:   Drug: Oral Ifetroban;   Drug: Oral Placebo
Sponsor:   Cumberland Pharmaceuticals
Recruiting - verified February 2017

A Study to Investigate the Effect of a Nitric Oxide Supplementation on Pre- and Mildly Hypertensive Adults

Condition:   Pre-hypertension
Interventions:   Dietary Supplement: Neo40 Daily®;   Dietary Supplement: Placebo
Sponsors:   KGK Synergize Inc.;   Neogenis Laboratories
Active, not recruiting - verified February 2017

Effects of Aerobic Exercise on Blood Pressure Levels of Resistant Hypertensive Subjects

Conditions:   Hypertension;   Resistant Hypertension
Intervention:   Behavioral: Aerobic Exercise Training
Sponsor:   Federal University of Paraíba
Active, not recruiting - verified February 2016

Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST

Condition:   Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
Interventions:   Drug: Placebo capsules;   Drug: Bardoxolone methyl capsules
Sponsor:   Reata Pharmaceuticals, Inc.
Recruiting - verified February 2017

Dexmedetomidine vs. Midazolam Sedation for Endobronchial Ultrasound

Conditions:   Conscious Sedation During Procedure;   Endobronchial Ultrasound
Interventions:   Drug: Dexmedetomidine;   Drug: Midazolam bolus;   Other: Saline placebo;   Drug: Rescue midazolam;   Drug: Fentanyl
Sponsor:   Postgraduate Institute of Medical Education and Research
Completed - verified February 2017

Postprandial Effects of a High Potassium Meal

Condition:   Hypertension
Interventions:   Other: High Potassium Meal;   Other: Low Potassium Meal
Sponsor:   Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Active, not recruiting - verified February 2017

A Study Investigating Routine Practice of Chronic Thromboembolic Pulmonary Hypertension Management in EMEA Countries

Condition:   Hypertension, Pulmonary
Intervention:   Other: Standard of care
Sponsor:   Bayer
Recruiting - verified February 2017

FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease

Condition:   Anemia
Interventions:   Drug: FG-4592;   Drug: Epoetin Alfa
Sponsor:   FibroGen
Active, not recruiting - verified February 2017

Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment

Condition:   Hypertension
Interventions:   Drug: telmisartan/amlodipine 40/5mg;   Drug: YH22162 40/5/12.5 mg;   Drug: telmisartan/amlodipine 80/5mg;   Drug: YH22162 80/5/25 mg;   Drug: telmisartan/amlodipine 40/5mg placebo;   Drug: YH22162 40/5/12.5 mg placebo;   Drug: telmisartan/amlodipine 80/5mg placebo;   Drug: YH22162 80/5/25 mg placebo
Sponsor:   Yuhan Corporation
Completed - verified February 2017

Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis

Conditions:   Renal Failure;   End Stage Renal Disease;   Hemodialysis;   Vascular Access
Interventions:   Biological: Human Acellular Vessel (HAV);   Device: ePTFE graft
Sponsors:   Humacyte, Inc.;   CTI Clinical Trial and Consulting Services
Recruiting - verified February 2017

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer

Conditions:   Breast Carcinoma;   Hypertension
Intervention:   Other: Laboratory Biomarker Analysis
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified February 2017

Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension

Condition:   Essential Hypertension
Interventions:   Drug: ERA;   Drug: Lisinopril;   Other: Placebo
Sponsor:   Actelion
Active, not recruiting - verified February 2017

Peripheral Chemoreflex/Arterial Baroreflex Interaction in Patients With Electrical Carotid Sinus Stimulation

Condition:   Hypertension, Resistant to Conventional Therapy
Interventions:   Other: Hypoxia without dopamine;   Other: Hypoxia with dopamine;   Other: Hyperoxia without dopamine;   Other: Hyperoxia with dopamine
Sponsors:   Hannover Medical School;   Charite University, Berlin, Germany;   Vanderbilt University School of Medicine;   Mayo Clinic;   University of Bristol
Recruiting - verified February 2017

iPhone App Compared to Standard RR-measurement

Conditions:   Hypertension;   Blood Pressure
Interventions:   Device: cuff device (Omron HBP-1300-E Pro);   Device: iPhone 4s
Sponsors:   Jens Eckstein;   Preventicus GmbH
Completed - verified February 2017

An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert

Conditions:   Primary Open-Angle Glaucoma;   Ocular Hypertension
Intervention:   Drug: Bimatoprost Ocular Insert
Sponsor:   ForSight Vision5, Inc.
Completed - verified February 2017

Egypt Hypertension Study

Condition:   Different Classes of the Antihypertensive Treatment
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified February 2017

Evaluation of the Heparin Binding Protein Levels in Sepsis

Conditions:   Sepsis;   Infection;   Septic Shock
Intervention:   Other: HBP lab test
Sponsor:   Christiana Care Health Services
Active, not recruiting - verified February 2017

Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis

Condition:   Hypertension, Portal
Interventions:   Drug: GR-MD-02;   Drug: Placebo
Sponsors:   Galectin Therapeutics Inc.;   Brooke Army Medical Center, Stephen A. Harrison, MD;   Indiana University
Active, not recruiting - verified February 2017

Prospective Safety and Tolerability Assessment of a Cardiovascular Health Dietary Supplement

Condition:   Hypertension
Intervention:   Dietary Supplement: Cardiovascular health dietary supplement
Sponsor:   National College of Natural Medicine
Active, not recruiting - verified February 2017

Community-based Management of Hypertension in Nepal

Condition:   Hypertension
Intervention:   Behavioral: FCHV visit
Sponsor:   University of Aarhus
Completed - verified February 2017

Mesenchymal Stem Cell Therapy for Bronchopulmonary Dysplasia in Preterm Babies

Condition:   Bronchopulmonary Dysplasia
Intervention:   Biological: Mesenchymal Stem Cell (MSC) therapy
Sponsors:   Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal;   Instituto de Salud Carlos III;   Fundación de Ayuda a la Investigación sobre la Hipertensión pulmonar
Not yet recruiting - verified February 2017

An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care Centres

Conditions:   Stroke;   Prevention and Control;   Atrial Fibrillation
Intervention:   Drug: Direct Oral Anticoagulant (DOAC)
Sponsor:   Bayer
Completed - verified February 2017

Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH)

Condition:   Hypertension, Pulmonary
Intervention:   Drug: Riociguat (ADEMPAS, BAY63-2521)
Sponsor:   Bayer
Recruiting - verified February 2017

Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)

Condition:   Thyroid Neoplasms
Intervention:   Drug: Lenvatinib
Sponsor:   Eisai Co., Ltd.
Recruiting - verified January 2017

Effects of Metoprolol and Amlodipine on Cardiac Remodeling, Arrhythmias and Blood Pressure Variation in Hypertensive Patients With Sleep Apnea Syndrome

Conditions:   Sleep Apnea Syndrome;   Hypertension
Interventions:   Drug: Amlodipine;   Drug: metoprolol
Sponsor:   First Affiliated Hospital of Harbin Medical University
Recruiting - verified October 2014

Radiofrequency Ablation for Multi-level Obstructive Sleep Apnea: A Single-arm, Multicenter Study

Condition:   Apnea, Sleep
Intervention:   Device: RFA treatment
Sponsor:   Olympus Surgical Technologies Europe
Recruiting - verified February 2017

Morbidity in Patients With Hypertension and Obstructive Sleep Apnea

Conditions:   Hypertension;   Sleep Apnea, Obstructive
Intervention:   Device: CPAP
Sponsors:   University of Sao Paulo General Hospital;   Financiadora de Estudos e Projetos;   Conselho Nacional de Desenvolvimento Científico e Tecnológico
Recruiting - verified February 2017

Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years

Condition:   PAH
Intervention:   Drug: oral treprostinil
Sponsor:   United Therapeutics
Active, not recruiting - verified February 2017

3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subjects Pulmonary Hypertension Associated With COPD and IPF

Conditions:   Pulmonary Hypertension;   Chronic Obstructive Pulmonary Disease;   Idiopathic Pulmonary Fibrosis
Interventions:   Drug: inhaled Nitric Oxide - 30 mcg/kg IBW/hr;   Drug: inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr;   Drug: inhaled nitric oxide 75 mcg/kg IBW/hr
Sponsor:   Bellerophon
Recruiting - verified February 2017

Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: Chemotherapy;   Drug: BI 695502;   Drug: bevacizumab;   Drug: Chemotherapy
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2017

Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

Condition:   Autosomal Dominant Polycystic Kidney Disease
Intervention:   Drug: Tolvaptan (OPC-41061)
Sponsor:   Otsuka Pharmaceutical Development & Commercialization, Inc.
Enrolling by invitation - verified February 2017

Long Term Outcomes of Venous Thromboembolism

Conditions:   Post Thrombotic Syndrome;   Chronic Thromboembolic Pulmonary Hypertension;   Venous Thrombosis
Intervention:  
Sponsor:   Ostfold Hospital Trust
Recruiting - verified February 2017

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Conditions:   Diabetes Mellitus, Type 2;   Hypertension
Interventions:   Drug: Empagliflizon low dose;   Drug: placebo;   Drug: Empagliflizon high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified February 2017

Azilsartan/Amlodipine Combination Tablets LD & HD Specified Drug-use Survey "Long-term Use Survey"

Condition:   Hypertension
Intervention:   Drug: Azilsartan/amlodipine
Sponsor:   Takeda
Active, not recruiting - verified February 2017

Comparison of Combigan BID Versus Simbrinza TID

Conditions:   Glaucoma;   Ocular Hypertension
Interventions:   Drug: Combigan BID;   Drug: Simbrinza TID
Sponsors:   Cornerstone Health Care, PA;   Allergan
Recruiting - verified February 2017

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Placebo
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified February 2017

An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product

Conditions:   Primary Open-Angle Glaucoma;   Ocular Hypertension
Intervention:   Drug: Bimatoprost Ocular Ring
Sponsor:   ForSight Vision5, Inc.
Completed - verified February 2017

Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH )

Condition:   Hypertension, Pulmonary
Intervention:   Drug: Riociguat (ADEMPAS, BAY63-2521)
Sponsor:   Bayer
Recruiting - verified February 2017

Registro Campania Salute Network on Hypertension

Condition:   Hypertension; Heart Disease, Hypertensive
Intervention:  
Sponsor:   Federico II University
Recruiting - verified February 2017

Randomized Double-blind Controlled Trial of Use of Dydrogesterone in Threatened Miscarriage

Condition:   Pregnancy
Interventions:   Drug: Dydrogesterone;   Drug: Placebo
Sponsor:   The University of Hong Kong
Recruiting - verified February 2017

EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension

Condition:   Hypertension, Pulmonary
Intervention:   Drug: Riociguat(BAY63-2521)
Sponsor:   Bayer
Recruiting - verified February 2017

The Mobile Health Platform

Conditions:   Obesity;   Hypertension;   Diabetes
Intervention:   Device: The Mobile Health Platform
Sponsor:   Duke University
Completed - verified October 2014

Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction

Condition:   Pulmonary Hypertension
Interventions:   Drug: Macitentan;   Drug: Placebo
Sponsor:   Actelion
Completed - verified February 2017

Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer

Condition:   Carcinoma, Hepatocellular
Interventions:   Drug: Everolimus;   Drug: Tacrolimus;   Drug: Myfortic;   Drug: CellCept;   Drug: Imuran
Sponsor:   Baylor Research Institute
Recruiting - verified February 2017

Renal Nerve Denervation in Patients With Hypertension and Paroxysmal and Persistent Atrial Fibrillation

Conditions:   Atrial Fibrillation;   Hypertension
Interventions:   Drug: Renal nerve denervation;   Device: Cryoablation
Sponsor:   Medtronic Atrial Fibrillation Solutions
Recruiting - verified February 2017

the Application of Cardiopulmonary Exercise Testing in Assessment Outcome of Patients With Pulmonary Hypertension

Condition:   Pulmonary Hypertension
Intervention:  
Sponsor:   Chinese Pulmonary Vascular Disease Research Group
Recruiting - verified February 2017

Prevention of Postpartum Hemorrhage in Patients With Severe Preeclampsia Using Carbetocin Versus Misoprostol

Condition:   Severe Pre-eclampsia, Postpartum Condition or Complication
Interventions:   Drug: misoprostol;   Drug: carbetocin
Sponsor:   khalid abd aziz mohamed
Completed - verified February 2017

Evaluation of a Non-Invasive Electrocardiogram-Assisted Blood Pressure Monitor

Conditions:   Hypertension;   Atrial Fibrillation;   Obesity;   Heart Failure;   Atherosclerosis
Intervention:  
Sponsor:   Health Parametrics Inc.
Terminated - verified February 2017

Evaluation of 3D Overlay During Transjugular Intrahepatic Portosystemic Shunt (TIPS) Procedure

Condition:   Portal Hypertension
Intervention:   Procedure: TIPS with 3D Overlay
Sponsors:   Medical College of Wisconsin;   Siemens Medical Solutions
Completed - verified February 2017

Novel Drug Delivery Technique Via Retroject Device

Condition:   Glaucoma
Interventions:   Device: Retroject Device;   Drug: ethacrynic acid injection;   Drug: balanced salt solution
Sponsor:   Molly Walsh
Completed - verified February 2017

Clinical Study to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension

Condition:   Chronic Thromboembolic Pulmonary Hypertension
Intervention:   Drug: Macitentan
Sponsor:   Actelion
Active, not recruiting - verified February 2017

Preventing Outcomes Through Effective Cardiovascular Risk Reduction After Transplant II

Condition:   Hypertension
Intervention:   Device: Ambulatory Blood Pressure Monitoring
Sponsor:   University of Michigan
Completed - verified February 2017

Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS

Condition:   Cirrhosis
Interventions:   Drug: Rifaximin;   Drug: placebo
Sponsor:   University Hospital, Toulouse
Recruiting - verified February 2017

Comparing Hydrus Microstent(TM) to the iStent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (COMPARE I)

Conditions:   Primary Open Angle Glaucoma;   Pseudoexfoliative Glaucoma;   Pigmentary Dispersion Glaucoma
Interventions:   Device: Hydrus Microstent;   Device: iStent Trabecular Micro Bypass
Sponsor:   Ivantis, Inc.
Active, not recruiting - verified February 2017

Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn

Condition:   Persistent Pulmonary Hypertension of the Newborn
Interventions:   Drug: IV Remodulin;   Drug: Placebo
Sponsor:   United Therapeutics
Recruiting - verified February 2017

Improved Cardiovascular Risk Reduction to Enhance Rural Primary Care

Conditions:   Diabetes Mellitus;   Hypertension;   Coronary Artery Disease;   Atrial Fibrillation;   Stroke
Interventions:   Other: PHCVRS Intervention;   Other: Personal Health Record
Sponsor:   Barry L. Carter
Active, not recruiting - verified February 2017

Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension

Condition:   Hypertension, Pulmonary
Intervention:   Drug: Iloprost (Ventavis, BAYQ6256)
Sponsor:   Bayer
Recruiting - verified February 2017

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Terminated - verified February 2017

Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis

Condition:   Anemia in Chronic Kidney Disease in Non-dialysis Patients
Interventions:   Drug: Roxadustat;   Drug: Placebo
Sponsors:   Astellas Pharma Europe B.V.;   FibroGen
Active, not recruiting - verified February 2017

A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)

Condition:   Hypertension, Pulmonary
Interventions:   Drug: Tadalafil;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified February 2017

A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based

Condition:   Kidney Transplantation
Interventions:   Drug: Belatacept;   Drug: Tacrolimus;   Drug: Cyclosporine
Sponsor:   Bristol-Myers Squibb
Recruiting - verified June 2016

Hormonal, Metabolic, and Signaling Interactions in PAH

Conditions:   Idiopathic Pulmonary Arterial Hypertension;   Heritable Pulmonary Arterial Hypertension;   Scleroderma Associated Pulmonary Arterial Hypertension;   Appetite Suppressant Associate PAH
Intervention:  
Sponsor:   Vanderbilt University
Recruiting - verified February 2017

Natural History Study of Biomarkers in Pulmonary Arterial Hypertension

Conditions:   Pulmonary Disease;   Pulmonary Hypertension
Intervention:  
Sponsor:   National Institutes of Health Clinical Center (CC)
Recruiting - verified November 16, 2016

Mitigation of Radiation Pneumonitis and Fibrosis

Conditions:   Lung Cancer;   Radiation Pneumonitis
Interventions:   Drug: Enalapril;   Drug: placebo
Sponsor:   VA Office of Research and Development
Recruiting - verified February 2017

Bevacizumab vs Dacarbazine in Metastatic Melanoma

Conditions:   Metastatic Malignant Melanoma;   Unresectable Malignant Melanoma
Interventions:   Drug: Bevacizumab;   Drug: Propranolol;   Drug: Enalapril;   Drug: Dacarbazine
Sponsors:   Haukeland University Hospital;   The Norwegian Melanoma Group;   Norwegian Cancer Society
Terminated - verified February 2017

Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers

Conditions:   Pre-eclampsia;   Intra-uterine Growth Restriction
Interventions:   Drug: Aspirin;   Drug: Placebo
Sponsor:   University Hospital, Tours
Completed - verified February 2017

A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn

Condition:   Pulmonary Hypertension, Familial Persistent, of the Newborn
Interventions:   Drug: placebo;   Drug: iv sildenafil
Sponsor:   Pfizer
Recruiting - verified February 2017

Renal Stent Placement for the Treatment of Renal Artery Stenosis in Patients With Resistant Hypertension

Conditions:   Renal Artery Stenosis;   Hypertension, Renovascular
Intervention:   Device: iCAST™ Rx Stent System
Sponsor:   Atrium Medical Corporation
Recruiting - verified February 2017

Phase 3 Study of Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis

Condition:   PBC
Interventions:   Drug: Bezafibrate;   Drug: placebo
Sponsor:   Assistance Publique - Hôpitaux de Paris
Completed - verified February 2017

Efficacy and Safety of a Therapy Change From Candesartan 32 mg to Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg

Condition:   Hypertension
Interventions:   Drug: Candesartan cilexetil;   Drug: Olmesartan medoxomil;   Drug: Olmesartan/amlodipine
Sponsor:   Institut für Pharmakologie und Präventive Medizin
Completed - verified February 2017

Amyloid Imaging and Cognitive Impairment After Intracerebral Hemorrhage

Condition:   Intracerebral Hemorrhage
Intervention:   Other: Pet AV-45
Sponsors:   University Hospital, Toulouse;   Avid Radiopharmaceuticals;   Institut National de la Santé Et de la Recherche Médicale, France
Recruiting - verified February 2017

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Conditions:   Type 2 Diabetes;   Chronic Kidney Disease
Interventions:   Drug: Dulaglutide;   Drug: Insulin glargine;   Drug: Insulin lispro
Sponsor:   Eli Lilly and Company
Completed - verified February 2017

Fibrosis a New Pathological Actor in Adipose Tissue

Conditions:   Obesity;   Metabolic Diseases;   Fibrosis;   Body Weight
Intervention:   Procedure: biopsy
Sponsor:   Assistance Publique - Hôpitaux de Paris
Recruiting - verified February 2017

Safety and Efficacy Trial to Evaluate the Hydrus(TM) Implant in Subjects Undergoing Cataract Surgery.

Conditions:   Primary Open Angle Glaucoma;   Glaucoma, Open Angle, Pseudo-exfoliative;   Cataract Unilateral Pending Extraction
Interventions:   Device: Hydrus Implant;   Procedure: IOL placement
Sponsor:   Ivantis, Inc.
Completed - verified February 2017

Telehealth & Remote Measurement Technologies to Improve Medication Adherence in Hypertension

Condition:   Hypertension
Interventions:   Behavioral: Computer Controlled Telephone Counseling;   Other: Physician information and management recommendations
Sponsor:   Boston Medical Center
Completed - verified February 2017

TRANSforming InTerprofessional Cardiovascular Prevention in Primary Care

Conditions:   Diabetes Mellitus, Type 2;   Hypertension;   Dyslipidemias;   Cholesterol, LDL;   Comorbitdity
Interventions:   Other: Facilitation;   Other: Passive diffusion
Sponsors:   Fonds de la Recherche en Santé du Québec;   Université de Montréal
Completed - verified February 2017

Treadmill Exercise and GM-CSF Study to Improving Functioning in Peripheral Artery Disease (PAD)

Condition:   Peripheral Arterial Disease
Interventions:   Behavioral: Supervised Treadmill Exercise Therapy;   Other: Health education sessions (Control);   Drug: granulocyte macrophage colony stimulating factor (GM-CSF)
Sponsors:   Northwestern University;   National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting - verified February 2017

Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Patients

Condition:   Pulmonary Arterial Hypertension
Intervention:   Drug: Imatinib
Sponsor:   Novartis Pharmaceuticals
Terminated - verified February 2017

SOLX Gold Shunt for Refractory Glaucoma

Conditions:   Glaucoma;   Glaucoma, Open Angle
Intervention:   Device: SOLX Gold Shunt
Sponsor:   SOLX, Inc.
Completed - verified February 2017

A National Multicentre Study to Assess the Efficacy of the Fixed Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled by Monotherapy

Condition:   Primary Hypertension
Intervention:   Drug: valsartan/amlodipine
Sponsor:   Novartis
Completed - verified February 2017

Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension

Condition:   Essential Hypertension
Intervention:   Drug: Ali/Amlo 150/2.5 mg
Sponsor:   Novartis Pharmaceuticals
Completed - verified February 2017

Prospective Retinal and Optic Nerve Vitrectomy Evaluation (PROVE) Study

Conditions:   Glaucoma;   Macular Pucker;   Macula Hole;   Vitreomacular Traction;   Vitreous Opacities or Hemorrhage
Intervention:  
Sponsor:   Vanderbilt University
Completed - verified February 2017

Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II Hypertension

Condition:   Stage II Hypertension
Intervention:   Drug: Aliskiren/Amlodipine (150/5 mg/day, 300/10 mg/day) , Aliskiren/Amlodipine/Hydrochlorothiazide (300/10/12.5 mg/day, 300/10/25 mg/day)
Sponsor:   Novartis
Completed - verified February 2017

A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients.

Condition:   High Blood Pressure
Intervention:   Drug: Aliskiren and HCTZ
Sponsor:   Novartis
Completed - verified February 2017

Trial Using Motivational Interviewing Positive Affect and Self-Affirmation in Hypertension (TRIUMPH)

Condition:   Hypertension
Interventions:   Behavioral: Positive Affect/Self-Affirmation/Motivational Interviewing;   Behavioral: Educational and Behavioral
Sponsors:   Weill Medical College of Cornell University;   National Institute on Minority Health and Health Disparities (NIMHD)
Completed - verified February 2017

Lifestyle Modification and Blood Pressure Study

Condition:   High Blood Pressure
Interventions:   Behavioral: Yoga exercise program;   Behavioral: Blood pressure education/walking program
Sponsor:   University of Pennsylvania
Completed - verified February 2017

BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension

Condition:   Pulmonary Hypertension
Intervention:   Drug: Riociguat (Adempas, BAY63-2521)
Sponsor:   Bayer
Active, not recruiting - verified February 2017

Functional and Cognitive Impairment in Advanced Kidney Disease

Condition:   Kidney Insufficiency, Chronic
Intervention:  
Sponsor:   VA Office of Research and Development
Active, not recruiting - verified February 2017

Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)

Condition:   Hypertension, Pulmonary
Intervention:   Drug: Riociguat (Adempas, BAY63-2521)
Sponsor:   Bayer
Active, not recruiting - verified February 2017

A New View of Normal Tension Glaucoma: Autoregulation and Systemic Blood Pressure

Condition:   Normal Tension Glaucoma
Intervention:  
Sponsor:   Weill Medical College of Cornell University
Completed - verified February 2017

Effect of Valsartan on Lipid Subfractions in Hypertensive Patients With Metabolic Syndrome

Conditions:   Hypertension;   Metabolic Syndrome
Intervention:   Drug: Valsartan
Sponsor:   Novartis
Completed - verified February 2017

Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.

Condition:   Essential Hypertension
Intervention:   Drug: Aliskiren
Sponsor:   Novartis
Completed - verified February 2017

Maternal and Umbilical Cord Hormone Concentrations in Twin and Singleton Pregnancies

Condition:   Normal Pregnancy
Intervention:  
Sponsor:   National Cancer Institute (NCI)
Completed - verified January 25, 2017

A Study of VAH631 in Patients With Essential Hypertension (Factorial Study)

Condition:   Hypertension
Interventions:   Drug: Valsartan;   Drug: Hydrochlorothiazide
Sponsor:   Novartis
Completed - verified February 2017

Effectiveness of a Valsartan Based vs an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy

Condition:   Hypertension
Interventions:   Drug: valsartan;   Drug: amlodipine
Sponsor:   Novartis
Completed - verified February 2017

A Randomized Trial of Changing Medication Adherence In Hypertensive African-American Patients

Condition:   Hypertension
Intervention:   Behavioral: Intervention Group
Sponsor:   Weill Medical College of Cornell University
Completed - verified February 2017

Study to Compare the Effect of Valsartan vs Atenolol on Pro-thrombotic State in Hypertensive Patients.

Condition:   Hypertension
Intervention:   Drug: valsartan/atenolol
Sponsor:   Novartis
Completed - verified February 2017

A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia

Conditions:   HYPERTENSION;   HYPERCHOLESTEROLEMIA
Intervention:   Drug: valsartan + simvastatin
Sponsor:   Novartis
Completed - verified February 2017

VALENCE: Valsartan Versus Atenolol on Exercise Capacity in Hypertensive Overweight Postmenopausal Women

Condition:   Hypertension
Interventions:   Drug: valsartan;   Drug: atenolol;   Drug: hydrochlorothiazide
Sponsor:   Novartis
Completed - verified February 2017

Antiproteinuric Effect of Valsartan and Lisinopril

Conditions:   Hypertension;   Diabetic Nephropathy
Interventions:   Drug: Valsartan;   Drug: Valsartan plus HCTZ;   Drug: Lisinopril
Sponsor:   Novartis
Completed - verified February 2017

Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension

Conditions:   Hypertension;   Left Ventricular Hypertrophy
Intervention:   Drug: amlodipine/benazepril
Sponsor:   Novartis
Completed - verified February 2017

Exploring Folk Health Practices in Latinos With Chronic Medical Conditions

Conditions:   Diabetes;   Hypertension;   Asthma;   Heart Disease;   Stroke;   Arthritis
Intervention:  
Sponsor:   Weill Medical College of Cornell University
Completed - verified February 2017